Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS).
Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions.
The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle.
The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs.
Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g.
NSAIDs
-Muscle-immune interactions during inflammation [...]
Abstracting & Indexing
ScopusGoogle ScholarWeb of ScienceMedlineEmbase
Detailed Metrics
Total Docs. (latest)
431
Total Docs. (3 years)
658
Total Refs.
38,834
Total Citations (3 years)
4,379
Citable Docs. (3 years)
645
Citations / Doc. (2 years)
6.79
Ref. / Doc.
90.10
% Female
46.2%
Metrics Visualization
Latest year data vs 3-year cumulative figures
Female: 46.2% |
Male: 53.9%
Citations / Doc. (2yr)6.79
High impact
References / Doc.90.10
High refs
Citable / Total Docs (3yr)98.0%
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Frequently Asked Questions
What is the impact factor of Inflammopharmacology?
The official Journal Impact Factor (JIF) is published by Clarivate in the Journal Citation Reports (JCR) and is not listed on this page. Based on SCImago data, Inflammopharmacology has an SJR of 1.373 and is ranked Q1.
What is the SJR and quartile of Inflammopharmacology?
Inflammopharmacology has an SJR (SCImago Journal Rank) of 1.373 and its best quartile is Q1.
What is the H-index of Inflammopharmacology?
The H-index of Inflammopharmacology is 81, meaning 81 of its articles have each been cited at least 81 times.
Is Inflammopharmacology indexed in Scopus?
Yes. Inflammopharmacology is active in Scopus (Scopus Source List, August 2026).